
MGRM
Monogram Technologies Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.750
Open
5.630
VWAP
5.68
Vol
114.82K
Mkt Cap
205.39M
Low
5.620
Amount
652.38K
EV/EBITDA(TTM)
--
Total Shares
31.67M
EV
192.12M
EV/OCF(TTM)
--
P/S(TTM)
--
Monogram Technologies Inc. is an artificial intelligence (AI)-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and robotics. The Company's mBos precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The Company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. It is also exploring other clinical and commercial applications for mBos with mVision navigation. Its mVision technology leverages AI-trained algorithms to track pre-identified objects in real-time.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.110
+37.5%
--
--
-0.100
-37.5%
--
--
-0.090
-18.18%
Estimates Revision
The market is revising No Change the revenue expectations for Monogram Technologies Inc. (MGRM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 91.25%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Up

+91.25%
In Past 3 Month
1 Analyst Rating

-4.93% Downside
Wall Street analysts forecast MGRM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGRM is 5.40 USD with a low forecast of 5.40 USD and a high forecast of 5.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

-4.93% Downside
Current: 5.680

Low
5.40
Averages
5.40
High
5.40

-4.93% Downside
Current: 5.680

Low
5.40
Averages
5.40
High
5.40
Roth MKM
Jason Wittes
Strong Buy
Maintains
$4 → $5.4
2025-03-18
Reason
Roth MKM
Jason Wittes
Price Target
$4 → $5.4
2025-03-18
Maintains
Strong Buy
Reason
Roth MKM raised the firm's price target on Monogram Orthopaedics to $5.40 from $4 and keeps a Buy rating on the shares. The company's announced FDA 510(k) clearance for its mBos TKA System, a robotic-assisted total knee arthroplasty platform with semi-autonomous cutting, is a major milestone de-risking the regulatory pathway, the analyst tells investors in a research note.
Roth MKM
Jason Wittes
Strong Buy
Initiates
$4
2024-12-09
Reason
Roth MKM
Jason Wittes
Price Target
$4
2024-12-09
Initiates
Strong Buy
Reason
Roth MKM analyst Jason Wittes initiated coverage of Monogram Orthopaedics with a Buy rating and $4 price target. The firm believes Monogram's mBos robotics platform simplifies surgery with autonomous cutting. It sees the company excelling in bone preparation and personalization, challenging Stryker's dominance in robotics.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Monogram Technologies Inc (MGRM.O) is -12.91, compared to its 5-year average forward P/E of -4.17. For a more detailed relative valuation and DCF analysis to assess Monogram Technologies Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-4.17
Current PE
-12.91
Overvalued PE
-1.22
Undervalued PE
-7.11
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.70
Current EV/EBITDA
-9.76
Overvalued EV/EBITDA
-1.06
Undervalued EV/EBITDA
-6.33
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
23.47
Current PS
209.13
Overvalued PS
63.13
Undervalued PS
-16.20
Financials
Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
-7.65%
-3.33M
Operating Profit
FY2025Q1
YoY :
-9.09%
-3.19M
Net Income after Tax
FY2025Q1
YoY :
-9.09%
-0.10
EPS - Diluted
FY2025Q1
YoY :
-32.55%
-2.47M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MGRM News & Events
Events Timeline
2025-07-14 (ET)
2025-07-14
07:39:29
Zimmer Biomet to acquire Monogram for $4.04 per share in cash upfront

2025-07-14
07:32:34
Zimmer Biomet to acquire Monogram Orthopaedics for $177M

2025-07-08 (ET)
2025-07-08
08:53:14
Monogram Orthopaedics announces conversion of Series D Preferred Stock

Sign Up For More Events
Sign Up For More Events
News
3.5
07-22NewsfilterFrom Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits
7.0
07-19GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SONN, FCCO, MGRM on Behalf of Shareholders
7.0
07-16GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAT, VBTX, MGRM on Behalf of Shareholders
Sign Up For More News
People Also Watch

XFOR
X4 Pharmaceuticals Inc
1.820
USD
-0.55%

RRGB
Red Robin Gourmet Burgers Inc
6.790
USD
-2.58%

GUTS
Fractyl Health Inc
1.920
USD
+0.52%

FAT
FAT Brands Inc
2.450
USD
+0.82%

ME
23andMe Holding Co.
0
USD
-27.05%

INZY
Inozyme Pharma Inc
0
USD
+0.25%

IMAB
I-Mab
2.110
USD
-0.47%

IH
Ihuman Inc
2.920
USD
-3.31%

BYNO
Bynordic Acquisition Corp
0
USD
-0.09%

GORV
Lazydays Holdings Inc
6.710
USD
-2.33%
FAQ

What is Monogram Technologies Inc (MGRM) stock price today?
The current price of MGRM is 5.68 USD — it has decreased -0.7 % in the last trading day.

What is Monogram Technologies Inc (MGRM)'s business?

What is the price predicton of MGRM Stock?

What is Monogram Technologies Inc (MGRM)'s revenue for the last quarter?

What is Monogram Technologies Inc (MGRM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Monogram Technologies Inc (MGRM)'s fundamentals?

How many employees does Monogram Technologies Inc (MGRM). have?
